Elite Pharmaceuticals, Inc. reported a significant increase in financial performance for the fiscal year ending March 31, 2025, with total revenues reaching $84.0 million, a 48% increase from $56.6 million in the previous year. This growth was primarily driven by the successful launch of four new products and increased sales from existing products. Manufacturing fees contributed $82.0 million to total revenue, reflecting a 51% increase, while licensing fees decreased by 18% to $2.1 million, attributed to a strategic shift away from licensing to focus on direct sales under the Elite label.
The company's gross profit also improved, rising to $40.1 million, or 48% of total revenue, compared to $26.4 million and 47% in the prior year. This increase in gross profit margin was due to higher manufacturing volumes and efficiencies achieved through increased production. However, operating expenses rose by 32% to $20.5 million, driven by higher research and development costs, general and administrative expenses, and a $1.6 million impairment related to intangible assets.
In terms of operational metrics, Elite Pharmaceuticals maintained a workforce of 68 full-time employees as of June 25, 2025. The company’s working capital increased to $45.9 million, up from $27.0 million the previous year, indicating improved liquidity. Despite these positive indicators, the company reported a net loss of $4.3 million, influenced by significant expenses related to the change in fair value of derivative financial instruments and interest expenses.
Strategically, Elite Pharmaceuticals has focused on expanding its product portfolio, with recent launches including generic versions of Percocet and other opioid medications. The company has also entered into various licensing and manufacturing agreements to enhance its market presence. However, it faces ongoing challenges, including regulatory scrutiny and potential litigation related to its opioid products, which could impact future revenues and operational stability.
Looking ahead, Elite Pharmaceuticals aims to continue its growth trajectory by leveraging its product pipeline and enhancing operational efficiencies. The company acknowledges the risks associated with regulatory changes and market competition but remains optimistic about its ability to navigate these challenges and achieve profitability in the future.
About ELITE PHARMACEUTICALS INC /NV/
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.